Results 181 to 190 of about 40,034 (308)

FUSION: a web-based application for in-depth exploration of multi-omics data with brightfield histology. [PDF]

Nat Commun
Border SP, Ferreira RM, Lucarelli N, Kumar SKC, Paul AS, Manthey D, Barisoni L, Levites Strekalova YA, Ray J, Cheng YH, Rosenberg AZ, Tomaszewski JE, Mimar S, Hodgin JB, Hickey JW, Wei B, Ginty F, Karunamurthy A, Wang J, Raina M, Pryhuber GS, Purkerson J, HuBMAP consortium, El-Achkar TM, Jain S, Eadon MT, Sarder P.   +26 more
europepmc   +1 more source

Human vs. artificial intelligence: Physicians outperform ChatGPT in real‐world pharmacotherapy counselling

British Journal of Clinical Pharmacology, EarlyView.
Aims To assess the utility of the artificial intelligence (AI) chatbot ChatGPT (openly available version 3.5) in responding to real‐world pharmacotherapeutic queries from healthcare professionals. Methods Three independent and blinded evaluators with different levels of medical expertise and professional experience (beginner, advanced, and expert ...
Benjamin Krichevsky, Stefan Engeli, Stefanie M. Bode‐Böger, Felix Koop, Martin Schulze Westhoff, Sebastian Schröder, Carsten Schumacher, Thorben Pape, Dirk O. Stichtenoth, Johannes Heck   +9 more
wiley   +1 more source

Lower Podocyte Number per Glomerulus Associates With Progressive CKD. [PDF]

Kidney Int Rep
Denic A, Shaik AA, Fareeduddin SK, Fnu A, Kumar M, Mullan AF, Sharma V, Alexander MP, Pandey A, Wiggins RC, Hodgin JB, Shankland SJ, Rule AD.   +12 more
europepmc   +1 more source

Gene Delivery into Rat Glomerulus Using a Mesangial Cell Vector

, 2000
Hey Jin Kim, Sung Il Kim, Ik Jin Yun, Joon Hyeok Kwak, Suk Hee Yu   +4 more
openalex   +1 more source

Translation of a physiologically‐based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post‐partum women

British Journal of Clinical Pharmacology, EarlyView.
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Kayode Ogungbenro, Lorna Aucott, Farhad Kamali, Paul Ayuk   +3 more
wiley   +1 more source

Type-specific molecular signaling architectures and synaptic plasticity of <i>Drosophila</i> olfactory sensory neurons. [PDF]

Front Cell Neurosci
Acharya N, Wiesel E, Selcho M, Ehmann N, Lamberty M, Hansson BS, Wicher D, Kittel RJ.   +7 more
europepmc   +1 more source

A real‐world data‐driven approach to optimizing enoxaparin dosing in burn patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Enoxaparin dosing in burn patients is challenging due to physiological changes affecting absorption, distribution and clearance. The objectives of this study are to develop a population pharmacokinetic (PK) model for enoxaparin in burn patients, evaluate target attainment with current equation‐based (EQ) dosing and propose an optimized dosing ...
Babajide Shenkoya, Venkata Yellepeddi, Ann Marie B. Prazak, Mathangi Gopalakrishnan   +3 more
wiley   +1 more source

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

Production of an inhibitor of rat mesangial cell growth by the glomerulus and its alteration in puromycin nephrosis. [PDF]

, 1993
Gerald C. Groggel, M. Laurette Hughes
openalex   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source